Investigating Cagrilintide's Effect on Bone Health in Obese Postmenopausal Women

Weight loss, particularly significant weight loss, can sometimes lead to adverse effects on bone mineral density, especially in vulnerable populations like postmenopausal women who are already at increased risk for osteoporosis and fractures. While new anti-obesity medications are highly effective at promoting weight reduction, their long-term impact on bone metabolism is a critical area of ongoing research. This Phase 1 clinical trial by Novo Nordisk aims to specifically address how cagrilintide, an amylin analogue, influences bone metabolism during weight loss in postmenopausal women with obesity, comparing its effects to semaglutide and placebo.

As this is a Phase 1 clinical trial, currently recruiting an estimated 144 participants, specific quantitative results regarding cagrilintide's impact on bone metabolism are not yet available. The study's primary objective is to assess the safety and tolerability of cagrilintide and its effects on various bone health markers in postmenopausal women with obesity during a period of induced weight loss. Researchers hypothesize that cagrilintide, an amylin analogue that complements GLP-1 by slowing gastric emptying and increasing satiety, may demonstrate a distinct and potentially more favorable effect on bone turnover compared to semaglutide or placebo. The study aims to determine if cagrilintide can mitigate potential bone loss associated with significant weight reduction, a common concern in postmenopausal women, by observing changes in bone formation and resorption markers over the study period, which is scheduled for completion in 2028. The trial will compare these bone health parameters across the cagrilintide, semaglutide, and placebo groups, seeking to identify any statistically significant differences in bone mineral density or turnover markers.